Advertisement

Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations

      Abstract

      Combined progestin–estrogen pills are an established and reliable contraceptive option used by women worldwide. Combined oral contraceptives (COCs) containing the progestins – gestodene, desogestrel or norgestimate – were developed to minimize androgenic side effects and are considered an effective, well-tolerated contraceptive option. Gestodene achieves contraceptive efficacy with the lowest dose of any progestin in a COC, and has an established and favorable short- and long-term tolerability profile. In this review we present an overview of the pharmacology, potency and tolerability of gestodene.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. UN Department of Economic and Social Affairs Population Division. World contraceptive use 2012 [cited Last accessed: 5 December 2012.].

        • Wiegratz I.
        • Thaler C.J.
        Hormonal contraception-what kind, when, and for whom?.
        Dtsch Arztebl Int. 2011; 108: 495-506
        • Darney P.D.
        The androgenicity of progestins.
        Am J Med. 1995; 98: 104S-110S
      2. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
        Lancet. 1995; 346: 1582-1588
        • Bloemenkamp K.W.
        • Rosendaal F.R.
        • Helmerhorst F.M.
        • Buller H.R.
        • Vandenbroucke J.P.
        Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
        Lancet. 1995; 346: 1593-1596
        • Jick H.
        • Jick S.S.
        • Gurewich V.
        • Myers M.W.
        • Vasilakis C.
        Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
        Lancet. 1995; 346: 1589-1593
        • Spitzer W.O.
        • Lewis M.A.
        • Heinemann L.A.
        • Thorogood M.
        • MacRae K.D.
        Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case–control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
        BMJ. 1996; 312: 83-88
      3. Regester M.L. Larkin J. Risk issues and crisis management: a casebook of best practice. Kogan Page Publishers, London2005
        • Poindexter A.N.
        Third-generation oral contraceptives and thromboembolism risk.
        Obstet Gynecol. 1997; 89: 1028-1030
        • Dusterberg B.
        • Beier S.
        • Schneider W.H.F.
        • Spona J.
        • Breckwoldt M.
        Pharmacological features of gestodene in laboratory animals and man.
        in: Breckwoldt M. Dusterberg B. Gestodene: A New Direction in Oral Contraception. Parthenon Publishing, Carnforth, Lancs, England1988: 13-29
        • Kuhl H.
        Pharmacology of estrogens and progestogens: influence of different routes of administration.
        Climacteric. 2005; 8: 3-63
        • Philibert D.
        • Bouchoux F.
        • Degryse M.
        • Lecaque D.
        • Petit F.
        • Gaillard M.
        The pharmacological profile of a novel norpregnance progestin (trimegestone).
        Gynecol Endocrinol. 1999; 13: 316-326
        • Stanczyk F.Z.
        • Hapgood J.P.
        • Winer Jr., S.
        • Mishell Jr., D.R.
        Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.
        Endocr Rev. 2013; 34: 171-208
        • Spona J.
        • Huber J.
        Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate.
        Gynecol Obstet Invest. 1987; 23: 184-193
        • Gaspard U.
        Progestogens in contraception: third-generation pills.
        in: Mishell Jr., D.R. Sitruk-Ware R. Progestins and anti-progestins in clinical practice. Marcel Dekker, Inc, New York2000: 179-215
        • Guengerich F.P.
        Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.
        Chem Res Toxicol. 1990; 3: 363-371
        • Kuhl H.
        Comparative pharmacology of newer progestogens.
        Drugs. 1996; 51: 188-215
        • Dusterberg B.
        • Tack J.-W.
        • Krause W.
        • Humpel M.
        Pharmacokinetics and biotransformation of gestodene in man.
        in: Elstein M. Gestodene: development of a new gestodene-containing low-dose oral contraceptive. Parthenon, London1987: 35-44
        • Tauber U.
        • Kuhnz W.
        • Humpel M.
        Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive.
        Am J Obstet Gynecol. 1990; 163: 1414
        • Tauber U.
        • Tack J.W.
        • Matthes H.
        Single dose pharmacokinetics of gestodene in women after intravenous and oral administration.
        Contraception. 1989; 40: 461-479
        • Orme M.
        • Back D.J.
        • Ward S.
        • Green S.
        The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
        Contraception. 1991; 43: 305-316
        • Kuhl H.
        • Jung-Hoffmann C.
        • Heidt F.
        Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene.
        Contraception. 1988; 38: 477-486
        • Fotherby K.
        Potency and pharmacokinetics of gestagens.
        Contraception. 1990; 41: 533-550
        • Dinger J.
        • Minh T.D.
        • Buttmann N.
        • Bardenheuer K.
        Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.
        Obstet Gynecol. 2011; 117: 33-40
        • Wilde M.I.
        • Balfour J.A.
        Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.
        Drugs. 1995; 50: 364-395
        • Godsland I.F.
        • Crook D.
        • Simpson R.
        • Proudler T.
        • Felton C.
        • Lees B.
        • et al.
        The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
        N Engl J Med. 1990; 323: 1375-1381
        • Miller V.T.
        Lipids, lipoproteins, women and cardiovascular disease.
        Atherosclerosis. 1994; 108: S73-S82
        • Yancey P.G.
        • Bortnick A.E.
        • Kellner-Weibel G.
        • de la Llera-Moya M.
        • Phillips M.C.
        • Rothblat G.H.
        Importance of different pathways of cellular cholesterol efflux.
        Arterioscler Thromb Vasc Biol. 2003; 23: 712-719
        • Fotherby K.
        • Caldwell A.D.
        New progestogens in oral contraception.
        Contraception. 1994; 49: 1-32
        • Yildizhan R.
        • Yildizhan B.
        • Adali E.
        • Yoruk P.
        • Birol F.
        • Suer N.
        Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
        Arch Gynecol Obstet. 2009; 280: 255-261
        • Speroff L.
        • DeCherney A.
        Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.
        Obstet Gynecol. 1993; 81: 1034-1047
        • Shoupe D.
        New progestins–clinical experiences: gestodene.
        Am J Obstet Gynecol. 1994; 170: 1562-1568
        • Winkler U.H.
        • Gaspard U.
        • Leidenberger F.
        The influence of a low-dose oral contraceptive containing 20mcg ethinylestradiol and 75mcg gestodene on lipid and carbohydrate metabolism.
        in: Lopes P. Killick S.R. The new option in low-dose oral contraception - expanding the gestodene choice. The Parthenon Publishing Group Limited, Carnforth, Lancs, England1995
        • Rabe T.
        • Runnebaum B.
        • Kohlmeier M.
        • Harenberg J.
        • Weicker H.
        Clinical and metabolic effects of gestodene and levonorgestrel.
        Int J Fertil. 1987; 32: 29-44
        • Wiegratz I.
        • Jung-Hoffmann C.
        • Gross W.
        • Kuhl H.
        Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
        Contraception. 1998; 58: 83-91
        • Kuhl H.
        • Marz W.
        • Jung-Hoffmann C.
        • Heidt F.
        • Gross W.
        Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
        Am J Obstet Gynecol. 1990; 163: 363-369
        • Skouby S.O.
        • Andersen O.
        • Petersen K.R.
        • Molsted-Pedersen L.
        • Kuhl C.
        Mechanism of action of oral contraceptives on carbohydrate metabolism at the cellular level.
        Am J Obstet Gynecol. 1990; 163: 343-348
        • Godsland I.F.
        • Walton C.
        • Felton C.
        • Proudler A.
        • Patel A.
        • Wynn V.
        Insulin resistance, secretion, and metabolism in users of oral contraceptives.
        J Clin Endocrinol Metab. 1992; 74: 64-70
        • Ludicke F.
        • Gaspard U.J.
        • Demeyer F.
        • Scheen A.
        • Lefebvre P.
        Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism.
        Contraception. 2002; 66: 411-415
        • Gaspard U.J.
        • Lefebvre P.J.
        Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
        Am J Obstet Gynecol. 1990; 163: 334-343
        • Spellacy W.N.
        • Tsibris A.M.
        • Tsibris J.C.
        • George S.
        • Chez R.A.
        • O'Brien W.F.
        Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol.
        Contraception. 1994; 49: 125-130
        • Cohen H.
        • Mackie I.J.
        • Walshe K.
        • Gillmer M.D.
        • Machin S.J.
        A comparison of the effects of two triphasic oral contraceptives on haemostasis.
        Br J Haematol. 1988; 69: 259-263
        • Ball M.J.
        • Ashwell E.
        • Jackson M.
        • Gillmer M.D.
        Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins.
        Contraception. 1990; 41: 363-376
        • Prasad R.N.
        • Koh S.C.
        • Viegas O.A.
        • Ratnam S.S.
        Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
        Clin Appl Thromb Hemost. 1999; 5: 60-70
        • Refn H.
        • Kjaer A.
        • Lebech A.M.
        • Borggaard B.
        • Schierup L.
        • Bremmelgaard A.
        Metabolic changes during treatment with two different progestogens.
        Am J Obstet Gynecol. 1990; 163: 374-377
        • Winkler U.H.
        • Schindler A.E.
        • Endrikat J.
        • Dusterberg B.
        A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
        Contraception. 1996; 53: 75-84
        • Lidegaard O.
        • Lokkegaard E.
        • Jensen A.
        • Skovlund C.W.
        • Keiding N.
        Thrombotic stroke and myocardial infarction with hormonal contraception.
        N Engl J Med. 2012; 366: 2257-2266
        • Lidegaard O.
        • Nielsen L.H.
        • Skovlund C.W.
        • Skjeldestad F.E.
        • Lokkegaard E.
        Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9.
        BMJ. 2011; 343: d6423
        • Heinemann L.A.
        • Dinger J.C.
        • Assmann A.
        • Minh T.D.
        Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
        Contraception. 2010; 81: 401-407
        • Dinger J.
        • Shapiro S.
        Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets.
        J Fam Plann Reprod Health Care. 2012; 38: 2-6
        • Dinger J.
        • Assmann A.
        • Mohner S.
        • Minh T.D.
        Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case–control study.
        J Fam Plann Reprod Health Care. 2010; 36: 123-129
        • Liu S.L.
        • Lebrun C.M.
        Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review.
        Br J Sports Med. 2006; 40: 11-24
        • Balasch J.
        Sex steroids and bone: current perspectives.
        Hum Reprod Update. 2003; 9: 207-222
        • Eriksen E.F.
        • Colvard D.S.
        • Berg N.J.
        • Graham M.L.
        • Mann K.G.
        • Spelsberg T.C.
        • et al.
        Evidence of estrogen receptors in normal human osteoblast-like cells.
        Science. 1988; 241: 84-86
        • Oursler M.J.
        • Osdoby P.
        • Pyfferoen J.
        • Riggs B.L.
        • Spelsberg T.C.
        Avian osteoclasts as estrogen target cells.
        Proc Natl Acad Sci U S A. 1991; 88: 6613-6617
        • Nappi C.
        • Di Spiezio Sardo A.
        • Greco E.
        • Tommaselli G.A.
        • Giordano E.
        • Guida M.
        Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
        Obstet Gynecol. 2005; 105: 53-60
        • Paoletti A.M.
        • Orru M.
        • Floris S.
        • Mannias M.
        • Vacca A.M.
        • Ajossa S.
        • et al.
        Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
        Contraception. 2000; 61: 259-263
        • Nappi C.
        • Di Spiezio Sardo A.
        • Acunzo G.
        • Bifulco G.
        • Tommaselli G.A.
        • Guida M.
        • et al.
        Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.
        Contraception. 2003; 67: 355-359
        • Caruso S.
        • Agnello C.
        • Intelisano G.
        • Farina M.
        • Di Mari L.
        • Cianci A.
        Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene.
        Contraception. 2004; 69: 237-240
        • Panzer C.
        • Wise S.
        • Fantini G.
        • Kang D.
        • Munarriz R.
        • Guay A.
        • et al.
        Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction.
        J Sex Med. 2006; 3: 104
        • Oranratanaphan S.
        • Taneepanichskul S.
        A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.
        J Med Assoc Thai. 2006; 89: S17-S22
        • Bancroft J.
        • Davidson D.W.
        • Warner P.
        • Tyrer G.
        Androgens and sexual behaviour in women using oral contraceptives.
        Clin Endocrinol (Oxf). 1980; 12: 327-340
        • Dei M.
        • Verni A.
        • Bigozzi L.
        • Bruni V.
        Sex steroids and libido.
        Eur J Contracept Reprod Health Care. 1997; 2: 253-258
        • Davis S.R.
        • Davison S.L.
        • Donath S.
        • Bell R.J.
        Circulating androgen levels and self-reported sexual function in women.
        JAMA. 2005; 294: 91-96
        • Trussell J.
        • Portman D.
        The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?.
        Contraception. 2013; 88: 604-610
        • Edelman A.B.
        • Carlson N.E.
        • Cherala G.
        • Munar M.Y.
        • Stouffer R.L.
        • Cameron J.L.
        • et al.
        Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.
        Contraception. 2009; 80: 119-127
        • Westhoff C.L.
        • Torgal A.H.
        • Mayeda E.R.
        • Petrie K.
        • Thomas T.
        • Dragoman M.
        • et al.
        Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women.
        Am J Obstet Gynecol. 2012; 207 (e1–6): 39
      4. Westhoff C, Reinecke I, Bangerter K, Merz M. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55 mg ethinyl estradiol/2.1 mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Manuscript in preparation. 2013.

        • Westhoff C.L.
        • Torgal A.T.
        • Mayeda E.R.
        • Shimoni N.
        • Stanczyk F.Z.
        • Pike M.C.
        Predictors of noncompliance in an oral contraceptive clinical trial.
        Contraception. 2012; 85: 465-469
        • Brill K.
        • Norpoth T.
        • Schnitker J.
        • Albring M.
        Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users.
        Contraception. 1991; 43: 101-110
        • Weber-Diehl F.
        • Unger R.
        • Lachnit U.
        Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial.
        Contraception. 1992; 46: 19-27
        • Affinito P.
        • Monterubbianesi M.
        • Primizia M.
        • Regine V.
        • Di Carlo C.
        • Farace M.J.
        • et al.
        Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
        Gynecol Endocrinol. 1993; 7: 259-266
        • Kirkman R.J.
        • Pedersen J.H.
        • Fioretti P.
        • Roberts H.E.
        Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
        Contraception. 1994; 49: 33-46
        • Loudon N.B.
        • Kirkman R.J.
        • Dewsbury J.A.
        A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30.
        Eur J Obstet Gynecol Reprod Biol. 1990; 34: 257-266
        • Weber-Diehl F.
        • Lehnert J.
        • Lachnit U.
        Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
        Contraception. 1993; 48: 291-301
        • Archer D.F.
        • Nakajima S.T.
        • Sawyer A.T.
        • Wentworth J.
        • Trupin S.
        • Koltun W.D.
        • et al.
        Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive.
        Obst Gynecol. 2013; 122: 601-607
        • Nakajima S.T.
        • Archer D.F.
        • Ellman H.
        Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
        Contraception. 2007; 75: 16-22
        • Archer D.F.
        Vascular dysfunction as a cause of endometrial bleeding.
        Gynecol Endocrinol. 2012; 28: 688-693
        • Rosenberg M.J.
        • Waugh M.S.
        • Higgins J.E.
        The effect of desogestrel, gestodene, and other factors on spotting and bleeding.
        Contraception. 1996; 53: 85-90
        • Kubba A.
        • Guillebaud J.
        Combined oral contraceptives: acceptability and effective use.
        Br Med Bull. 1993; 49: 140-157
        • Nichols M.
        • Robinson G.
        • Bounds W.
        • Newman B.
        • Guillebaud J.
        Effect of four combined oral contraceptives on blood pressure in the pill-free interval.
        Contraception. 1993; 47: 367-376
        • Farmer R.D.
        • Lawrenson R.A.
        • Todd J.C.
        • Williams T.J.
        • MacRae K.D.
        • Tyrer F.
        • et al.
        A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
        Br J Clin Pharmacol. 2000; 49: 580-590
        • Heinemann L.A.
        • Dinger J.C.
        Range of published estimates of venous thromboembolism incidence in young women.
        Contraception. 2007; 75: 328-336
        • Fruzzetti F.
        • Ricci C.
        • Fioretti P.
        Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
        Contraception. 1994; 49: 579-592
        • Suissa S.
        • Spitzer W.O.
        • Rainville B.
        • Cusson J.
        • Lewis M.
        • Heinemann L.
        Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.
        Hum Reprod. 2000; 15: 817-821
        • Catherino W.H.
        • Jeng M.H.
        • Jordan V.C.
        Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.
        Br J Cancer. 1993; 67: 945-952
        • van der Burg B.
        • Kalkhoven E.
        • Isbrucker L.
        • de Laat S.W.
        Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions.
        J Steroid Biochem Mol Biol. 1992; 42: 457-465
        • Strom B.L.
        • Berlin J.A.
        • Weber A.L.
        • Norman S.A.
        • Bernstein L.
        • Burkman R.T.
        • et al.
        Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
        Contraception. 2004; 69: 353-360
        • Li C.I.
        • Beaber E.F.
        • Tang M.T.
        • Porter P.L.
        • Daling J.R.
        • Malone K.E.
        Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age.
        Cancer Res. 2012; 72: 2028-2035
        • Hannaford P.
        Health consequences of combined oral contraceptives.
        Br Med Bull. 2000; 56: 749-760
        • Moreno V.
        • Bosch F.X.
        • Munoz N.
        • Meijer C.J.
        • Shah K.V.
        • Walboomers J.M.
        • et al.
        Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case–control study.
        Lancet. 2002; 359: 1085-1092
        • Vessey M.P.
        • Painter R.
        Endometrial and ovarian cancer and oral contraceptives–findings in a large cohort study.
        Br J Cancer. 1995; 71: 1340-1342
        • Back D.J.
        • Houlgrave R.
        • Tjia J.F.
        • Ward S.
        • Orme M.L.
        Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes.
        J Steroid Biochem Mol Biol. 1991; 38: 219-225
        • Stanczyk F.Z.
        Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.
        Contraception. 1997; 55: 273-282
        • Palovaara S.
        • Kivisto K.T.
        • Tapanainen P.
        • Manninen P.
        • Neuvonen P.J.
        • Laine K.
        Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation.
        Br J Clin Pharmacol. 2000; 50: 333-337
        • Jones E.E.
        Androgenic effects of oral contraceptives: implications for patient compliance.
        Am J Med. 1995; 98: 116S-119S
        • Lidegaard O.
        • Lokkegaard E.
        • Svendsen A.L.
        • Agger C.
        Hormonal contraception and risk of venous thromboembolism: national follow-up study.
        BMJ. 2009; 339: b2890